Sodium-glucose co-transporter-2 inhibitors: A paradigm shift in treatment for type 2 diabetes.

Matthews DR.

DOI

10.1111/dom.15963

Type

Journal article

Publication Date

2024-10-01T00:00:00+00:00

Volume

26 Suppl 5

Pages

3 - 4

Total pages

1

Keywords

SGLT2 inhibitor, canagliflozin, cardiovascular disease, heart failure, Humans, Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Hypoglycemic Agents, Sodium-Glucose Transporter 2, Blood Glucose

Permalink More information Close